Managing Rett syndrome involves a comprehensive approach that combines symptom control, therapeutic support, and emerging treatments aimed at improving quality of life and maximizing each individual’s potential.

Pathways to Better Living with Rett Syndrome

When a family receives a Rett syndrome diagnosis, understanding the treatment landscape becomes crucial. While there is currently no cure for this rare neurological disorder, the focus of care centers on managing symptoms, preventing complications, and enhancing the daily experiences of those affected. Treatment strategies are highly individualized because Rett syndrome affects each person differently, with symptoms ranging from mild to severe^[1].

The main goals of treatment include improving movement and coordination, supporting communication abilities, managing seizures and other medical complications, and providing ongoing care that adapts as needs change over time. Because Rett syndrome impacts multiple body systems, effective care requires a team approach involving specialists from various medical disciplines^[2].

Standard treatments approved by medical societies form the foundation of care, addressing specific symptoms as they arise. At the same time, research into new therapies continues to advance, with clinical trials exploring innovative approaches that target the underlying mechanisms of the disorder. This combination of established symptom management and cutting-edge research offers hope for better outcomes^[3].

Standard Treatment Approaches

The cornerstone of Rett syndrome treatment involves managing individual symptoms through a combination of medications and supportive therapies. Since the disorder affects multiple aspects of health, treatment plans must address various complications that can arise throughout a person’s life^[4].

For seizures, which affect many individuals with Rett syndrome, doctors prescribe anticonvulsant medications (drugs that prevent or reduce the severity of seizures). The specific medication chosen depends on the type and frequency of seizures. Common options include medications that work by stabilizing electrical activity in the brain. The dosage is carefully adjusted for each patient, and regular monitoring helps ensure the medication remains effective while minimizing side effects. Some people may need to try different medications before finding the most effective option^[5].

Breathing irregularities, including periods of rapid breathing or breath-holding, can cause significant distress. While no specific medication directly treats these breathing problems, managing anxiety with selective serotonin reuptake inhibitors (a class of medications that affect brain chemistry to reduce anxiety) can sometimes help. These medications work by increasing the availability of serotonin, a chemical messenger in the brain that influences mood and behavior^[13].

Gastrointestinal issues are common and often challenging. Many individuals experience gastroesophageal reflux (a condition where stomach acid flows back into the food pipe, causing discomfort) and constipation. Treatment includes medications that reduce stomach acid production and therapies that promote regular bowel movements. Dietary modifications, guided by nutrition specialists, play an important role in managing these symptoms while ensuring adequate calorie intake and healthy weight maintenance^[6].

Heart rhythm abnormalities require careful monitoring through regular electrocardiograms. Some individuals may need medications to regulate heart rhythm, particularly if they have QT syndrome (a heart condition that affects the electrical system and can lead to dangerous irregular heartbeats). This condition requires ongoing surveillance because it can increase the risk of serious complications^[4].

Physical therapy represents a vital component of standard care. Therapists work to maintain and improve motor skills, prevent muscle contractures (permanent tightening of muscles and joints), and address mobility challenges. Sessions may include exercises to strengthen muscles, improve balance, and maintain flexibility. The intensity and type of exercises are adjusted as the person moves through different stages of the syndrome^[11].

Occupational therapy focuses on improving hand function and supporting independence in daily activities. Since Rett syndrome causes loss of purposeful hand use and characteristic repetitive hand movements like wringing or clapping, occupational therapists develop strategies to maximize remaining hand function. They also introduce adaptive equipment and techniques to assist with self-feeding, dressing, and other activities of daily living^[17].

Speech and communication therapy addresses the significant language impairments associated with Rett syndrome. While most individuals with the condition are non-verbal, they possess the ability to learn alternative communication methods. Therapists introduce augmentative and alternative communication systems (tools and strategies that help people communicate without speaking), including eye-gaze technology, picture boards, and electronic communication devices. These tools enable individuals to express their needs, preferences, and thoughts, dramatically improving quality of life^[17].

Nutritional support is essential because many individuals struggle with chewing, swallowing, and maintaining adequate weight. Dietitians develop specialized feeding plans that ensure sufficient intake of calories, calcium, vitamin D, and fiber. Some individuals may require modified food textures or supplemental nutrition to prevent malnutrition and support bone health^[9].

Orthopedic interventions become necessary when scoliosis develops. This sideways curvature of the spine is common in Rett syndrome and typically appears after age six. Treatment may begin with bracing to slow the progression of the curve. In more severe cases, surgical correction may be recommended to prevent the curve from interfering with breathing and other vital functions^[5].

The duration of these treatments varies significantly. Some interventions, like physical and occupational therapy, continue throughout life with adjustments made based on changing needs. Medications may be long-term or adjusted periodically depending on symptom control and the development of new complications. The care approach remains flexible, responding to the individual’s evolving needs across their lifespan^[11].

Breakthrough Approved Treatment

In March 2023, a major milestone occurred in Rett syndrome treatment when the United States Food and Drug Administration approved trofinetide, marketed under the name Daybue. This represents the first-ever drug specifically approved for treating Rett syndrome, marking a significant shift from purely symptom-based management to a treatment that addresses underlying disease mechanisms^[13].

Trofinetide works through multiple pathways in the brain. It reduces inflammation in brain tissue, prevents certain types of cells from becoming overactive, and increases levels of a naturally occurring protein called insulin-like growth factor 1 (IGF-1), which plays important roles in brain development and function. By targeting these specific pathways related to the MECP2 gene mutation that causes Rett syndrome, trofinetide represents a disease-modifying therapy rather than simply treating symptoms^[13].

The medication is administered as a liquid taken twice daily by mouth. It is approved for use in adults and children aged two years and older with Rett syndrome. The treatment is designed to be ongoing, similar to how people with diabetes or multiple sclerosis take medications continuously to modify how their disease works in the body^[13].

Clinical trial results showed that parents and caregivers noticed improvements in several important areas after their children took trofinetide. These improvements included better presence and engagement with their surroundings, enhanced communication abilities, more reliable use of communication devices, improved fine motor skills including better ability to grasp objects or feed themselves, better eye contact, fewer breath-holding episodes, and more regulated behavior overall. The changes were measured through questionnaires completed by parents and caregivers who observed their children in daily life^[13].

UCSF Benioff Children’s Hospital participated in the Phase 2 clinical trial for trofinetide from 2016 to 2017, contributing to the research that eventually led to FDA approval. The hospital’s Katie’s Clinic for Rett Syndrome has been designated a center of excellence by the International Rett Syndrome Foundation, offering this treatment as part of comprehensive care^[13].

The approval of trofinetide has brought renewed hope to the Rett community. It validates years of research into understanding the biological basis of the disorder and demonstrates that treatments targeting underlying mechanisms can make meaningful differences. While trofinetide does not cure Rett syndrome, it represents an important step forward in improving quality of life for those affected^[15].

Experimental Treatments in Clinical Trials

The research landscape for Rett syndrome has become increasingly active, with multiple innovative therapies currently being tested in clinical trials. These experimental approaches aim to address the root cause of the disorder rather than just managing symptoms, offering the possibility of more substantial improvements in function and quality of life^[15].

Gene therapy approaches are among the most promising areas of investigation. Since Rett syndrome results from mutations in the MECP2 gene, researchers are developing methods to deliver working copies of this gene directly into brain cells. These therapies use specially modified viruses as vehicles to carry the correct genetic material into neurons. The goal is to restore normal production of the MeCP2 protein, which is essential for proper brain function. Early-phase trials are evaluating the safety of different delivery methods and doses^[15].

Several experimental approaches involve sophisticated genetic editing techniques. Base editing is a technology that can change individual letters in the genetic code without cutting the DNA strand. Researchers are exploring whether this approach could correct the specific mutations that cause Rett syndrome. Prime editing represents an even newer technology that can make precise changes to DNA, potentially fixing mutations with greater accuracy than earlier methods. These technologies are still in laboratory development stages but show considerable promise^[1].

Another innovative approach focuses on MECP2 reactivation. Women with Rett syndrome have two copies of the X chromosome, but typically only one is active in each cell due to a normal process called X-inactivation. In Rett syndrome, the chromosome carrying the mutated gene may be the active one in many cells. Researchers are investigating whether it might be possible to reactivate the X chromosome carrying the normal gene, effectively bypassing the mutation. This strategy could potentially benefit females with Rett syndrome without requiring gene insertion or editing^[1].

RNA-based therapies represent another exciting frontier. RNA editing techniques aim to correct the messenger RNA produced by the mutated gene before it is translated into protein. RNA trans-splicing is a related approach that involves replacing defective portions of RNA with correct sequences. These methods work at a step between the gene itself and the final protein product, potentially offering advantages in terms of safety and reversibility compared to permanent DNA changes^[1].

Small molecule drugs that target specific biological pathways disrupted in Rett syndrome are also under investigation. These medications aim to compensate for the loss of normal MeCP2 function by enhancing or suppressing activity of related proteins and pathways in the brain. Some experimental compounds focus on improving the function of nerve cell connections (synapses), while others aim to reduce inflammation or oxidative stress in the nervous system. These drugs would have the advantage of being easier to administer than gene therapies, potentially as pills or liquids taken orally^[15].

Clinical trials for Rett syndrome typically progress through distinct phases. Phase I trials focus primarily on safety, testing the experimental treatment in a small number of participants to identify appropriate doses and watch for side effects. Phase II trials expand to larger groups to begin evaluating whether the treatment shows signs of effectiveness while continuing to monitor safety. Phase III trials compare the new treatment directly against standard care or placebo in even larger groups of participants to definitively determine effectiveness and safety. The trofinetide trials that led to FDA approval progressed through all these phases^[13].

Research sites conducting Rett syndrome clinical trials are located throughout the United States, Europe, and other regions globally. Major academic medical centers with specialized Rett syndrome clinics often serve as trial sites. The International Rett Syndrome Foundation maintains a registry and provides information about ongoing trials, helping families connect with research opportunities. Eligibility criteria vary by study but typically include factors such as confirmed MECP2 mutation, age range, ability to participate in testing procedures, and sometimes specific symptom profiles^[11].

The increasing focus on Rett syndrome by pharmaceutical companies and academic researchers reflects growing recognition that advances in this rare disorder could have implications far beyond just Rett syndrome. Because the condition results from a single known gene mutation with clear effects on brain development and function, it serves as a valuable model for understanding how genes control nervous system function. Successful treatments for Rett syndrome could advance therapeutic approaches for other neurological conditions affecting millions more people^[15].

Most common treatment methods

• Medication management
  • Anticonvulsant medications to control seizures, with specific drugs chosen based on seizure type and frequency
  • Selective serotonin reuptake inhibitors to manage anxiety and potentially reduce breathing irregularities
  • Acid suppression therapy for gastroesophageal reflux and medications to address constipation
  • Heart rhythm medications for individuals with QT syndrome or other cardiac irregularities
  • Trofinetide (Daybue), the first FDA-approved disease-modifying treatment specifically for Rett syndrome
• Physical rehabilitation therapies
  • Physical therapy to maintain mobility, prevent muscle contractures, and improve balance and coordination
  • Occupational therapy to maximize hand function and support independence in daily activities
  • Hydrotherapy (water-based therapy) to take advantage of buoyancy for movements difficult on land
  • Therapeutic horseback riding to improve posture, muscle strength, and quality of life
• Communication support
  • Speech-language therapy focusing on non-verbal communication methods
  • Augmentative and alternative communication systems including eye-gaze technology
  • Picture boards and electronic communication devices to enable expression of needs and preferences
• Nutritional interventions
  • Specialized feeding plans to ensure adequate calorie intake and healthy weight maintenance
  • Modified food textures for individuals with chewing and swallowing difficulties
  • Supplementation with calcium, vitamin D, and fiber to support bone health and digestive function
• Orthopedic management
  • Bracing to slow progression of scoliosis in its early stages
  • Surgical correction for severe spinal curves that interfere with breathing and function
• Experimental gene-based therapies
  • Gene therapy using viral vectors to deliver working copies of the MECP2 gene to brain cells
  • Base editing and prime editing techniques to correct specific genetic mutations
  • MECP2 reactivation strategies to activate the normal gene copy on the inactive X chromosome
  • RNA editing and RNA trans-splicing to correct messenger RNA before protein production